signalTechCrunch AI2026-09-24
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised $311 million in a Series E at a $2 billion valuation, double its valuation from 12 months ago. The round was led by Catalio Capital Management with participation from Iconiq and others. The AI biotech uses technology to discover medicines from plants and microbes, and is advancing several candidates into human trials, including for skin conditions and weight loss maintenance after GLP-1s.
- for who
- Biotech investors and AI drug discovery professionals
- why now
- Enveda's $311M raise doubles valuation in a year, signaling AI drug discovery momentum.
- what changes
- They see AI-discovered drugs moving into clinical trials, raising confidence in the approach
- to do
- Track Enveda's clinical trial progress to observe the real-world impact of AI in drug discovery
key points
- Enveda raised $311M Series E at $2B valuation, doubling last year's
- Led by Catalio, with Iconiq and others participating
- AI discovers drugs from plants and microbes, targeting skin conditions and GLP-1 weight maintenance
#ai drug discovery#biotech#funding
score
score 8 out of 10. 0-10: how dense the facts are, multiplied by how much you can do with them after reading. 8+ means the topic's evidence bar is met: benchmarks and availability for a new model, amount and investors for a funding round, revenue figures for a solo-money story. Below 5 an item does not enter the digest. A press release scores 3 or less, a reprint loses 2, anything older than 14 days loses 1, a headline that misleads loses 3.
read the source